Caversham HC Consortium Limited 07545254 false 2024-05-01 2025-04-30 2025-04-30 The principal activity of the company is that of a retail pharmacy until 1 May 2020, when the trade, assets and liabilities were transferred to Enimed Limited. Digita Accounts Production Advanced 6.30.9574.0 true true 07545254 2024-05-01 2025-04-30 07545254 2025-04-30 07545254 bus:OrdinaryShareClass1 bus:CumulativeShares 2025-04-30 07545254 bus:OrdinaryShareClass2 bus:CumulativeShares 2025-04-30 07545254 bus:OrdinaryShareClass3 bus:CumulativeShares 2025-04-30 07545254 core:ShareCapital 2025-04-30 07545254 core:CurrentFinancialInstruments 2025-04-30 07545254 core:CurrentFinancialInstruments core:WithinOneYear 2025-04-30 07545254 bus:SmallEntities 2024-05-01 2025-04-30 07545254 bus:AuditExemptWithAccountantsReport 2024-05-01 2025-04-30 07545254 bus:FilletedAccounts 2024-05-01 2025-04-30 07545254 bus:SmallCompaniesRegimeForAccounts 2024-05-01 2025-04-30 07545254 bus:RegisteredOffice 2024-05-01 2025-04-30 07545254 bus:Director1 2024-05-01 2025-04-30 07545254 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-05-01 2025-04-30 07545254 bus:OrdinaryShareClass2 bus:CumulativeShares 2024-05-01 2025-04-30 07545254 bus:OrdinaryShareClass3 bus:CumulativeShares 2024-05-01 2025-04-30 07545254 bus:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 07545254 core:ParentEntities 2024-05-01 2025-04-30 07545254 countries:EnglandWales 2024-05-01 2025-04-30 07545254 2023-05-01 2024-04-30 07545254 2024-04-30 07545254 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-04-30 07545254 bus:OrdinaryShareClass2 bus:CumulativeShares 2024-04-30 07545254 bus:OrdinaryShareClass3 bus:CumulativeShares 2024-04-30 07545254 core:CurrentFinancialInstruments core:WithinOneYear 2024-04-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 07545254

Prepared for the registrar

Caversham HC Consortium Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 30 April 2025

 

Caversham HC Consortium Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 5

 

Caversham HC Consortium Limited

Company Information

Director

Mr V Patel

Registered office

109-111 Field End Road
Pinner
Middlesex
HA5 1QG

Accountants

Hazlewoods LLP
Staverton Court
Staverton
Cheltenham
GL51 0UX

 

Caversham HC Consortium Limited

(Registration number: 07545254)
Balance Sheet as at 30 April 2025

Note

2025
£

2024
£

Current assets

 

Debtors

4

38,374

38,374

Capital and reserves

 

Called up share capital

5

2,031,137

2,031,137

Retained earnings

(1,992,763)

(1,992,763)

Shareholders' funds

 

38,374

38,374

For the financial year ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 10 December 2025
 


Mr V Patel
Director

 

Caversham HC Consortium Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2025

 

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
109-111 Field End Road
Pinner
Middlesex
HA5 1QG
England

 

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Going concern

After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Critical accounting judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
 

Judgements

No significant judgements have been made by management in preparing these financial statements.

Key sources of estimation uncertainty

No key sources of estimation uncertainty have been identified by management in preparing these financial statements other than those detailed in these accounting policies.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

 

Caversham HC Consortium Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2025

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Financial instruments


Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.


Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.


Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

 

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was as follows:

 

Caversham HC Consortium Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2025

 

5

Share capital

Allotted, called up and fully paid shares

 

2025

2024

 

No.

£

No.

£

Ordinary A shares of £1 each

55,000

55,000

55,000

55,000

Ordinary B shares of £1 each

45,000

45,000

45,000

45,000

Ordinary C shares of £1 each

1,931,137

1,931,137

1,931,137

1,931,137

 

2,031,137

2,031,137

2,031,137

2,031,137

The shares above carry separate rights in respect of dividends, however, in all other aspects rank pari passu.

 

6

Related party transactions

Summary of transactions with parent

Enimed Limited
 (Parent company)
At the balance sheet date the company was owed £38,374 by Enimed Limited (2024 - £38,374). There are no fixed repayment terms and no interest is charged on the loan